137 related articles for article (PubMed ID: 33345476)
21. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
22. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A
Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer.
Jang TL; Patel N; Faiena I; Radadia KD; Moore DF; Elsamra SE; Singer EA; Stein MN; Eastham JA; Scardino PT; Lin Y; Kim IY; Lu-Yao GL
Cancer; 2018 Oct; 124(20):4010-4022. PubMed ID: 30252932
[TBL] [Abstract][Full Text] [Related]
24. Tailored treatment including radical prostatectomy and radiation therapy + androgen deprivation therapy versus exclusive radical prostatectomy in high-risk prostate cancer patients: results from a prospective study.
Castelli T; Russo GI; Favilla V; Urzi D; Spitaleri F; Reale G; Giardina R; Saita A; Madonia M; Cimino S; Morgia G
Int Braz J Urol; 2014; 40(3):322-9. PubMed ID: 25010298
[TBL] [Abstract][Full Text] [Related]
25. Early endocrine therapy versus radical prostatectomy combined with early endocrine therapy for stage D1 prostate cancer.
Schmeller N; Lubos W
Br J Urol; 1997 Feb; 79(2):226-34. PubMed ID: 9052475
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer.
Mizowaki T; Norihisa Y; Takayama K; Ikeda I; Inokuchi H; Nakamura K; Kamba T; Inoue T; Kamoto T; Ogawa O; Hiraoka M
Int J Clin Oncol; 2016 Feb; 21(1):148-55. PubMed ID: 26141133
[TBL] [Abstract][Full Text] [Related]
27. Long-term results of radical prostatectomy with immediate adjuvant androgen deprivation therapy for pT3N0 prostate cancer.
Tsurumaki Sato Y; Fukuhara H; Suzuki M; Fujimura T; Nakagawa T; Nishimatsu H; Kume H; Morikawa T; Fukayama M; Homma Y
BMC Urol; 2014 Jan; 14():13. PubMed ID: 24476554
[TBL] [Abstract][Full Text] [Related]
28. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy.
Hirano D; Okada Y; Minei S; Takimoto Y; Nemoto N
Eur Urol; 2004 May; 45(5):586-92; discussion 592. PubMed ID: 15082200
[TBL] [Abstract][Full Text] [Related]
29. Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy.
Yoo S; You D; Kim YS; Hong JH; Ahn H; Kim CS
Urol Int; 2017; 99(4):406-413. PubMed ID: 29020683
[TBL] [Abstract][Full Text] [Related]
30. Induction androgen deprivation therapy before radical prostatectomy for prostate cancer--initial results.
Abbas F; Kaplan M; Soloway MS
Br J Urol; 1996 Mar; 77(3):423-8. PubMed ID: 8814850
[TBL] [Abstract][Full Text] [Related]
31. Large cell differentiation of metastatic prostate cancer after androgen deprivation therapy.
Patel R; Faiena I; Geltzeiler J
Can J Urol; 2015 Apr; 22(2):7752-4. PubMed ID: 25891342
[TBL] [Abstract][Full Text] [Related]
32. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
Mottet N; Peneau M; Mazeron JJ; Molinie V; Richaud P
Eur Urol; 2012 Aug; 62(2):213-9. PubMed ID: 22502942
[TBL] [Abstract][Full Text] [Related]
33. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
34. Quality of Life after Radical Prostatectomy or Watchful Waiting With or Without Androgen Deprivation Therapy: The SPCG-4 Randomized Trial.
Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Bill-Axelson A;
Eur Urol Oncol; 2018 Jun; 1(2):134-142. PubMed ID: 31100237
[TBL] [Abstract][Full Text] [Related]
35. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
36. Large-cell neuroendocrine carcinoma of prostate. Case report.
Moratalla Charcos LM; Pastor Navarro T; Cortes Vizcaino V; Osca Garcia JM; Gil Salom M
Arch Esp Urol; 2013 May; 66(4):368-71. PubMed ID: 23676541
[TBL] [Abstract][Full Text] [Related]
37. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.
Kumar S; Shelley M; Harrison C; Coles B; Wilt TJ; Mason MD
Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD006019. PubMed ID: 17054269
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant radiation, chemotherapy, and androgen deprivation therapy for pathologic stage D1 adenocarcinoma of the prostate.
Freeman JA; Lieskovsky G; Grossfeld G; Esrig D; Stein JP; Cook DW; Petrovich Z; Chen SC; Groshen S; Skinner DG
Urology; 1994 Nov; 44(5):719-25. PubMed ID: 7526528
[TBL] [Abstract][Full Text] [Related]
39. Combination of adjuvant radiotherapy and androgen deprivation therapy after radical prostatectomy in high risk prostate cancer patients - results from retrospective analysis.
Omrcen T; Hrepic D; Boraska Jelavic T; Vrdoljak E
J BUON; 2015; 20(4):1061-7. PubMed ID: 26416057
[TBL] [Abstract][Full Text] [Related]
40. [Risk factors for early castration-resistant prostate cancer after androgen deprivation therapy for bone-metastatic prostate cancer].
Huang FM; Li XH; Liang Y
Zhonghua Nan Ke Xue; 2018 Aug; 24(8):690-694. PubMed ID: 30173426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]